Results 281 to 290 of about 4,375,182 (366)

Hallmarks of Neuroblastoma—Pathophysiology, Diagnosis, and Therapeutic Interventions

open access: yesCancer Nexus, EarlyView.
ABSTRACT Neuroblastoma, the most common extracranial solid tumor in childhood, continues to challenge clinicians and researchers because of its heterogeneous nature and complex pathophysiology. Recent breakthroughs in molecular profiling revealed intricate genetic alterations driving tumor progression, necessitating an updated perspective on the ...
Abhimanyu Thakur, Anne Dijkstra
wiley   +1 more source

Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Alemtuzumab is a T cell‐depleting monoclonal antibody that is used for the prevention of kidney transplant rejection. The duration of lymphodepletion after the current standard induction therapy dose is likely longer than necessary, resulting in prolonged T cell lymphopenia with the associated risk of infections. Here, the interplay between alemtuzumab
Lukas K. van Vugt   +8 more
wiley   +1 more source

Autologous peripheral blood progenitor cell transplantation mobilized with high-dose cytarabine in acute myeloid leukemia in first complete remission

open access: bronze, 1998
S Pavlovsky   +8 more
openalex   +1 more source

Combinatorial expression of glial transcription factors induces Schwann cell‐specific gene expression in mouse embryonic fibroblasts

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background Schwann cells provide peripheral nerve trophic support, myelinate axons, and assist in repair. However, Schwann cell repair capacity is limited by chronic injury, disease, and aging. Schwann cell reprogramming is a cellular conversion strategy that could provide a renewable cell supply to repair injured nerves.
Lauren Belfiore   +7 more
wiley   +1 more source

Rapid lntraoperative Construction of Autologous Small Caliber Blood Vessels

open access: bronze, 1998
Charles S. Love   +4 more
openalex   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy